| First Author | Omori K | Year | 2023 |
| Journal | Oncogene | Volume | 42 |
| Issue | 33 | Pages | 2485-2494 |
| PubMed ID | 37402881 | Mgi Jnum | J:339725 |
| Mgi Id | MGI:7524055 | Doi | 10.1038/s41388-023-02761-z |
| Citation | Omori K, et al. (2023) C/ebpalpha represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development. Oncogene 42(33):2485-2494 |
| abstractText | Osteosarcoma (OS) is characterized by TP53 mutations in humans. In mice, loss of p53 triggers OS development, and osteoprogenitor-specific p53-deleted mice are widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms underlying the initiation or progression of OS following or parallel to p53 inactivation remain largely unknown. Here, we examined the role of transcription factors involved in adipogenesis (adipo-TFs) in p53-deficient OS and identified a novel tumor suppressive molecular mechanism mediated by C/ebpalpha. C/ebpalpha specifically interacts with Runx3, a p53 deficiency-dependent oncogene, and, in the same manner as p53, decreases the activity of the oncogenic axis of OS, Runx3-Myc, by inhibiting Runx3 DNA binding. The identification of a novel molecular role for C/ebpalpha in p53-deficient osteosarcomagenesis underscores the importance of the Runx-Myc oncogenic axis as a therapeutic target for OS. |
